Search

Your search keyword '"Lebrun-Frenay, Christine"' showing total 611 results

Search Constraints

Start Over You searched for: Author "Lebrun-Frenay, Christine" Remove constraint Author: "Lebrun-Frenay, Christine"
611 results on '"Lebrun-Frenay, Christine"'

Search Results

3. The diagnostic workup of children with the radiologically isolated syndrome differs by age and by sex

6. Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort

12. Effects of socioeconomic status on excess mortality in patients with multiple sclerosis in France: a retrospective observational cohort study

14. From the prodromal stage of multiple sclerosis to disease prevention

17. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

18. Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study

19. Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing–Remitting Multiple Sclerosis After Fingolimod Withdrawal

22. Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference

25. Kappa Free Light Chain Biomarkers Are Efficient for the Diagnosis of Multiple Sclerosis: A Large Multicenter Cohort Study

29. Aquaporin 4 distribution in the brain and its relevance for the radiological appearance of neuromyelitis optica spectrum disease

31. Relapses in Patients Treated with High-Dose Biotin for Progressive Multiple Sclerosis

32. Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple Sclerosis.

34. Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society

35. COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022

36. Time to move past typical syndromes in the diagnosis of multiple sclerosis.

40. Comparison of 2 Methods for Estimating Multiple Sclerosis–Related Mortality

42. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

45. The biological sample collection of the OFSEP French MS registry: An essential tool dedicated to researchers

48. High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS

49. Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance

Catalog

Books, media, physical & digital resources